Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
In a so-called real world study, the anti-coagulant did better in reducing the risk of strokes or major bleeds compared to warfarin than did J&J's competing Xarelto or Boehringer's&nb...
MONDAY, March 20, 2017 -- Patients undergoing a surgical procedure to treat an irregular heartbeat are less likely to suffer problematic bleeding when given the blood thinner Pradaxa rather than warfa...
Data from a late-stage trial show that Bayer and Janssen’s Xarelto was better than aspirin at protecting patients from recurrent venous thromboembolism.
Janssen and Bayer have stopped a phase 3 trial of Xarelto early after results showed it can cut deaths, heart attacks and strokes compared to aspirin. The promising data paves the way for a lucrativ...
A former Bayer sales rep says he was forced to gather patient data that was used to prepare medical journal papers for promoting the Xarelto blood thinner.
The Phase III trial COMPASS evaluating the efficacy and safety of Xarelto (rivaroxaban) for the prevention…
NewsPharmaceutical company Boehringer Ingelheim Pharmaceuticals Inc., presented two studies at the American Society of Hematology Annual Meeting in San Diego, which showed patients who were newly diag...
Bayer has been putting its blood-thinning drug, Xarelto, through its paces in a Phase 3 trial to determine whether it could help patients at risk from heart attacks and strokes due to a type of artery...
Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...